{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:42:55Z","timestamp":1792788175293,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82070223"],"award-info":[{"award-number":["No. 82070223"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"crossref","award":["No. BK20241119"],"award-info":[{"award-number":["No. BK20241119"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Social Development Project of Jiangsu Science and Technology Plan","award":["No. BK20220718"],"award-info":[{"award-number":["No. BK20220718"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-025-02158-3","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T14:18:05Z","timestamp":1742998685000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Exosome-transmitted HSPA9 facilitates bortezomib resistance by targeting TRIP13\/USP1 signaling in multiple myeloma"],"prefix":"10.1186","volume":"23","author":[{"given":"Min","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiapei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuxing","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"issue":"5","key":"2158_CR1","first-page":"497","volume":"327","author":"J Silberstein","year":"2022","unstructured":"Silberstein J, Tuchman S, Grant SJ. What Is Multiple Myeloma? JAMA. 2022;327(5):497.","journal-title":"What Is Multiple Myeloma? JAMA"},{"issue":"12","key":"2158_CR2","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.6004\/jnccn.2023.0061","volume":"21","author":"SK Kumar","year":"2023","unstructured":"Kumar SK, Callander NS, Adekola K, Anderson LJ, Baljevic M, Baz R, Campagnaro E, Castillo JJ, Costello C, D\u2019Angelo C, et al. Multiple myeloma, version 2.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023;21(12):1281\u2013301.","journal-title":"J Natl Compr Canc Netw"},{"issue":"19","key":"2158_CR3","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1182\/blood.2023019758","volume":"142","author":"AM Poos","year":"2023","unstructured":"Poos AM, Prokoph N, Przybilla MJ, Mallm JP, Steiger S, Seufert I, John L, Tirier SM, Bauer K, Baumann A, et al. Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysis. Blood. 2023;142(19):1633\u201346.","journal-title":"Blood"},{"key":"2158_CR4","doi-asserted-by":"publisher","first-page":"103950","DOI":"10.1016\/j.ebiom.2022.103950","volume":"78","author":"Z Yu","year":"2022","unstructured":"Yu Z, Wei X, Liu L, Sun H, Fang T, Wang L, Li Y, Sui W, Wang K, He Y, et al. Indirubin-3\u2019-monoxime acts as proteasome inhibitor: therapeutic application in multiple myeloma. EBioMedicine. 2022;78:103950.","journal-title":"EBioMedicine"},{"key":"2158_CR5","doi-asserted-by":"crossref","unstructured":"Kozalak G, Butun I, Toyran E, Kosar A. Review on bortezomib resistance in multiple myeloma and potential role of emerging technologies. Pharmaceuticals (Basel). 2023; 16(1):111\u2013132.","DOI":"10.3390\/ph16010111"},{"issue":"34","key":"2158_CR6","doi-asserted-by":"publisher","first-page":"4929","DOI":"10.1038\/onc.2017.105","volume":"36","author":"YL Hsu","year":"2017","unstructured":"Hsu YL, Hung JY, Chang WA, Lin YS, Pan YC, Tsai PH, Wu CY, Kuo PL. Hypoxic lung cancer-secreted Exosomal miR-23a increased angiogenesis and vascular permeability by targeting Prolyl hydroxylase and tight junction protein ZO-1. Oncogene. 2017;36(34):4929\u201342.","journal-title":"Oncogene"},{"key":"2158_CR7","doi-asserted-by":"publisher","first-page":"6999","DOI":"10.1038\/ncomms7999","volume":"6","author":"H Shao","year":"2015","unstructured":"Shao H, Chung J, Lee K, Balaj L, Min C, Carter BS, Hochberg FH, Breakefield XO, Lee H, Weissleder R. Chip-based analysis of Exosomal mRNA mediating drug resistance in glioblastoma. Nat Commun. 2015;6:6999.","journal-title":"Nat Commun"},{"issue":"1","key":"2158_CR8","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1186\/s12967-021-03124-6","volume":"19","author":"P Shi","year":"2021","unstructured":"Shi P, Li Y, Guo Q, Circular. RNA circPIP5K1A contributes to cancer stemness of osteosarcoma by miR-515-5p\/YAP axis. J Transl Med. 2021;19(1):464.","journal-title":"J Transl Med"},{"issue":"1","key":"2158_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12951-023-01801-w","volume":"21","author":"X Liu","year":"2023","unstructured":"Liu X, Guo Q, Gao G, Cao Z, Guan Z, Jia B, Wang W, Zhang K, Zhang W, Wang S, et al. Exosome-transmitted circCABIN1 promotes Temozolomide resistance in glioblastoma via sustaining erbb downstream signaling. J Nanobiotechnol. 2023;21(1):45.","journal-title":"J Nanobiotechnol"},{"issue":"1","key":"2158_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13045-019-0739-0","volume":"12","author":"Q Wu","year":"2019","unstructured":"Wu Q, Zhou L, Lv D, Zhu X, Tang H. Exosome-mediated communication in the tumor microenvironment contributes to hepatocellular carcinoma development and progression. J Hematol Oncol. 2019;12(1):53.","journal-title":"J Hematol Oncol"},{"issue":"9","key":"2158_CR11","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s12276-022-00839-4","volume":"54","author":"X Wang","year":"2022","unstructured":"Wang X, Huang J, Chen W, Li G, Li Z, Lei J. The updated role of Exosomal proteins in the diagnosis, prognosis, and treatment of cancer. Exp Mol Med. 2022;54(9):1390\u2013400.","journal-title":"Exp Mol Med"},{"issue":"11","key":"2158_CR12","doi-asserted-by":"publisher","first-page":"152603","DOI":"10.1016\/j.prp.2019.152603","volume":"215","author":"Y Wu","year":"2019","unstructured":"Wu Y, Zhu X, Shen R, Huang J, Xu X, He S. miR-182 contributes to cell adhesion-mediated drug resistance in multiple myeloma via targeting PDCD4. Pathol Res Pract. 2019;215(11):152603.","journal-title":"Pathol Res Pract"},{"issue":"8","key":"2158_CR13","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1158\/1541-7786.MCR-15-0135","volume":"13","author":"SP Shah","year":"2015","unstructured":"Shah SP, Lonial S, Boise LH. When cancer fights back: multiple myeloma, proteasome Inhibition, and the Heat-Shock response. Mol Cancer Res. 2015;13(8):1163\u201373.","journal-title":"Mol Cancer Res"},{"issue":"8","key":"2158_CR14","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.chembiol.2022.06.010","volume":"29","author":"ID Ferguson","year":"2022","unstructured":"Ferguson ID, Lin YT, Lam C, Shao H, Tharp KM, Hale M, Kasap C, Mariano MC, Kishishita A, Patino EB, et al. Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma. Cell Chem Biol. 2022;29(8):1288\u2013e13027.","journal-title":"Cell Chem Biol"},{"key":"2158_CR15","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/978-3-030-40204-4_10","volume":"1243","author":"S Kambhampati","year":"2020","unstructured":"Kambhampati S, Wiita AP. Lessons Learned from Proteasome Inhibitors, the Paradigm for Targeting Protein Homeostasis in Cancer. Adv Exp Med Biol. 2020;1243:147\u201362.","journal-title":"Adv Exp Med Biol"},{"key":"2158_CR16","doi-asserted-by":"crossref","unstructured":"Kabakov AE, Gabai VL. HSP70s in Breast Cancer: Promoters of Tumorigenesis and Potential Targets\/Tools for Therapy. Cells. 2021; 10(12):3446\u20133489.","DOI":"10.3390\/cells10123446"},{"issue":"21","key":"2158_CR17","doi-asserted-by":"publisher","first-page":"4257","DOI":"10.1038\/s41388-020-1285-5","volume":"39","author":"PK Wu","year":"2020","unstructured":"Wu PK, Hong SK, Starenki D, Oshima K, Shao H, Gestwicki JE, Tsai S, Park JI. Mortalin\/HSPA9 targeting selectively induces KRAS tumor cell death by perturbing mitochondrial membrane permeability. Oncogene. 2020;39(21):4257\u201370.","journal-title":"Oncogene"},{"issue":"3","key":"2158_CR18","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.gendis.2022.01.002","volume":"10","author":"P Ding","year":"2023","unstructured":"Ding P, Ma Z, Fan Y, Feng Y, Shao C, Pan M, Zhang Y, Huang D, Han J, Hu Y, Yan X. Emerging role of ubiquitination\/deubiquitination modification of PD-1\/PD-L1 in cancer immunotherapy. Genes Dis. 2023;10(3):848\u201363.","journal-title":"Genes Dis"},{"issue":"3","key":"2158_CR19","doi-asserted-by":"publisher","first-page":"101077","DOI":"10.1016\/j.jbc.2021.101077","volume":"297","author":"NA Snyder","year":"2021","unstructured":"Snyder NA, Silva GM. Deubiquitinating enzymes (DUBs): Regulation, homeostasis, and oxidative stress response. J Biol Chem. 2021;297(3):101077.","journal-title":"J Biol Chem"},{"key":"2158_CR20","doi-asserted-by":"crossref","unstructured":"Vaithiyanathan M, Yu Y, Rahnama A, Pettigrew JH, Safa N, Liu D, Gauthier TJ, Floyd ZE, Melvin AT. Characterization of PMI-5011 on the Regulation of Deubiquitinating Enzyme Activity in Multiple Myeloma Cell Extracts. Biochem Eng J. 2021; 166:107834\u2013107859.","DOI":"10.1016\/j.bej.2020.107834"},{"issue":"7","key":"2158_CR21","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.1007\/s10238-023-01075-4","volume":"23","author":"P Huang","year":"2023","unstructured":"Huang P, Wang Y, Zhang P, Li Q. Ubiquitin-specific peptidase 1: assessing its role in cancer therapy. Clin Exp Med. 2023;23(7):2953\u201366.","journal-title":"Clin Exp Med"},{"issue":"15","key":"2158_CR22","doi-asserted-by":"publisher","first-page":"4280","DOI":"10.1158\/1078-0432.CCR-16-2692","volume":"23","author":"DS Das","year":"2017","unstructured":"Das DS, Das A, Ray A, Song Y, Samur MK, Munshi NC, Chauhan D, Anderson KC. Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells. Clin Cancer Res. 2017;23(15):4280\u20139.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2158_CR23","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.7150\/ijbs.65428","volume":"18","author":"P Yuan","year":"2022","unstructured":"Yuan P, Feng Z, Huang H, Wang G, Chen Z, Xu G, Xie Z, Jie Z, Zhao X, Ma Q, et al. USP1 inhibition suppresses the progression of osteosarcoma via destabilizing TAZ. Int J Biol Sci. 2022;18(8):3122\u201336.","journal-title":"Int J Biol Sci"},{"issue":"3","key":"2158_CR24","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s00412-015-0516-y","volume":"124","author":"G Vader","year":"2015","unstructured":"Vader G. Pch2(TRIP13): controlling cell division through regulation of HORMA domains. Chromosoma. 2015;124(3):333\u20139.","journal-title":"Chromosoma"},{"issue":"7","key":"2158_CR25","first-page":"4397","volume":"11","author":"S Lu","year":"2019","unstructured":"Lu S, Guo M, Fan Z, Chen Y, Shi X, Gu C, Yang Y. Elevated TRIP13 drives cell proliferation and drug resistance in bladder cancer. Am J Transl Res. 2019;11(7):4397\u2013410.","journal-title":"Am J Transl Res"},{"key":"2158_CR26","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.csbj.2019.06.005","volume":"17","author":"S Lu","year":"2019","unstructured":"Lu S, Qian J, Guo M, Gu C, Yang Y. Insights into a Crucial Role of TRIP13 in Human Cancer. Comput Struct Biotechnol J. 2019;17:854\u201361.","journal-title":"Comput Struct Biotechnol J"},{"issue":"6","key":"2158_CR27","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","volume":"109","author":"JJ Shaughnessy","year":"2007","unstructured":"Shaughnessy JJ, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, Stewart JP, Kordsmeier B, Randolph C, Williams DR, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109(6):2276\u201384.","journal-title":"Blood"},{"issue":"1","key":"2158_CR28","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ccr.2012.12.001","volume":"23","author":"W Zhou","year":"2013","unstructured":"Zhou W, Yang Y, Xia J, Wang H, Salama ME, Xiong W, Xu H, Shetty S, Chen T, Zeng Z, et al. NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers. Cancer Cell. 2013;23(1):48\u201362.","journal-title":"Cancer Cell"},{"key":"2158_CR29","doi-asserted-by":"crossref","unstructured":"Li C, Xia J, Franqui-Machin R, Chen F, He Y, Ashby TC, Teng F, Xu H, Liu D, Gai D et al. TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignancies. J Clin Invest. 2021; 131(14):e146893\u2013906.","DOI":"10.1172\/JCI146893"},{"issue":"7","key":"2158_CR30","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1038\/s41375-023-01925-w","volume":"37","author":"L Xu","year":"2023","unstructured":"Xu L, Wang Y, Wang G, Guo S, Yu D, Feng Q, Hu K, Chen G, Li B, Xu Z, et al. Aberrant activation of TRIP13-EZH2 signaling axis promotes stemness and therapy resistance in multiple myeloma. Leukemia. 2023;37(7):1576\u20139.","journal-title":"Leukemia"},{"issue":"12","key":"2158_CR31","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos M, Kumar S, Hillengass J, Kastritis E, Richardson P, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538\u201348.","journal-title":"Lancet Oncol"},{"issue":"11","key":"2158_CR32","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1021\/acscentsci.7b00224","volume":"3","author":"FM Tomlin","year":"2017","unstructured":"Tomlin FM, Gerling-Driessen U, Liu YC, Flynn RA, Vangala JR, Lentz CS, Clauder-Muenster S, Jakob P, Mueller WF, Ordonez-Rueda D, et al. Inhibition of NGLY1 Inactivates the Transcription Factor Nrf1 and Potentiates Proteasome Inhibitor Cytotoxicity. ACS Cent Sci. 2017;3(11):1143\u201355.","journal-title":"ACS Cent Sci"},{"issue":"13","key":"2158_CR33","doi-asserted-by":"publisher","first-page":"3040","DOI":"10.1182\/blood-2008-08-172734","volume":"113","author":"G Bianchi","year":"2009","unstructured":"Bianchi G, Oliva L, Cascio P, Pengo N, Fontana F, Cerruti F, Orsi A, Pasqualetto E, Mezghrani A, Calbi V, et al. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood. 2009;113(13):3040\u20139.","journal-title":"Blood"},{"key":"2158_CR34","doi-asserted-by":"publisher","first-page":"869","DOI":"10.3389\/fonc.2019.00869","volume":"9","author":"J Ni","year":"2019","unstructured":"Ni J, Bucci J, Malouf D, Knox M, Graham P, Li Y. Exosomes in Cancer Radioresistance. Front Oncol. 2019;9:869.","journal-title":"Front Oncol"},{"issue":"14","key":"2158_CR35","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1182\/blood-2018-06-859686","volume":"133","author":"J Zhuang","year":"2019","unstructured":"Zhuang J, Shirazi F, Singh RK, Kuiatse I, Wang H, Lee HC, Berkova Z, Berger A, Hyer M, Chattopadhyay N, et al. Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma. Blood. 2019;133(14):1572\u201384.","journal-title":"Blood"},{"key":"2158_CR36","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.lfs.2019.02.003","volume":"221","author":"T Chen","year":"2019","unstructured":"Chen T, Zhang G, Kong L, Xu S, Wang Y, Dong M. Leukemia-derived exosomes induced IL-8 production in bone marrow stromal cells to protect the leukemia cells against chemotherapy. Life Sci. 2019;221:187\u201395.","journal-title":"Life Sci"},{"issue":"11","key":"2158_CR37","doi-asserted-by":"publisher","first-page":"10773","DOI":"10.1007\/s13277-014-2377-z","volume":"35","author":"MM Lv","year":"2014","unstructured":"Lv MM, Zhu XY, Chen WX, Zhong SL, Hu Q, Ma TF, Zhang J, Chen L, Tang JH, Zhao JH. Exosomes mediate drug resistance transfer in MCF-7 breast cancer cells and a probable mechanism is delivery of P-glycoprotein. Tumour Biol. 2014;35(11):10773\u20139.","journal-title":"Tumour Biol"},{"issue":"4","key":"2158_CR38","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ccr.2014.03.007","volume":"25","author":"W Zhou","year":"2014","unstructured":"Zhou W, Fong MY, Min Y, Somlo G, Liu L, Palomares MR, Yu Y, Chow A, O\u2019Connor ST, Chin AR, et al. Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell. 2014;25(4):501\u201315.","journal-title":"Cancer Cell"},{"issue":"6","key":"2158_CR39","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1158\/1078-0432.CCR-18-2363","volume":"25","author":"H Xu","year":"2019","unstructured":"Xu H, Han H, Song S, Yi N, Qian C, Qiu Y, Zhou W, Hong Y, Zhuang W, Li Z, et al. Exosome-Transmitted PSMA3 and PSMA3-AS1 Promote Proteasome Inhibitor Resistance in Multiple Myeloma. Clin Cancer Res. 2019;25(6):1923\u201335.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2158_CR40","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1038\/sj.leu.2404253","volume":"20","author":"I Hanamura","year":"2006","unstructured":"Hanamura I, Huang Y, Zhan F, Barlogie B, Shaughnessy J. Prognostic value of cyclin D2 mRNA expression in newly diagnosed multiple myeloma treated with high-dose chemotherapy and tandem autologous stem cell transplantations. Leukemia. 2006;20(7):1288\u201390.","journal-title":"Leukemia"},{"key":"2158_CR41","doi-asserted-by":"publisher","first-page":"12050","DOI":"10.1038\/ncomms12050","volume":"7","author":"JS Mitchell","year":"2016","unstructured":"Mitchell JS, Li N, Weinhold N, Forsti A, Ali M, van Duin M, Thorleifsson G, Johnson DC, Chen B, Halvarsson BM, et al. Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. Nat Commun. 2016;7:12050.","journal-title":"Nat Commun"},{"issue":"14","key":"2158_CR42","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1182\/blood-2009-03-211045","volume":"115","author":"JJ Driscoll","year":"2010","unstructured":"Driscoll JJ, Pelluru D, Lefkimmiatis K, Fulciniti M, Prabhala RH, Greipp PR, Barlogie B, Tai YT, Anderson KC, Shaughnessy JJ, et al. The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome. Blood. 2010;115(14):2827\u201334.","journal-title":"Blood"},{"issue":"1","key":"2158_CR43","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41556-019-0442-y","volume":"22","author":"CS Clairmont","year":"2020","unstructured":"Clairmont CS, Sarangi P, Ponnienselvan K, Galli LD, Csete I, Moreau L, Adelmant G, Chowdhury D, Marto JA. D\u2019Andrea AD. TRIP13 regulates DNA repair pathway choice through REV7 conformational change. Nat Cell Biol. 2020;22(1):87\u201396.","journal-title":"Nat Cell Biol"},{"key":"2158_CR44","doi-asserted-by":"publisher","first-page":"4527","DOI":"10.1038\/ncomms5527","volume":"5","author":"R Banerjee","year":"2014","unstructured":"Banerjee R, Russo N, Liu M, Basrur V, Bellile E, Palanisamy N, Scanlon CS, van Tubergen E, Inglehart RC, Metwally T, et al. TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer. Nat Commun. 2014;5:4527.","journal-title":"Nat Commun"},{"key":"2158_CR45","doi-asserted-by":"crossref","unstructured":"Chen S, Liu Y, Zhou H. Advances in the Development Ubiquitin-Specific Peptidase (USP) Inhibitors. Int J Mol Sci. 2021; 22(9):4546\u201374.","DOI":"10.3390\/ijms22094546"},{"issue":"21","key":"2158_CR46","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1093\/nar\/gkac805","volume":"50","author":"W Qin","year":"2022","unstructured":"Qin W, Steinek C, Kolobynina K, Forne I, Imhof A, Cardoso MC, Leonhardt H. Probing protein ubiquitination in live cells. Nucleic Acids Res. 2022;50(21):e125.","journal-title":"Nucleic Acids Res"},{"key":"2158_CR47","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1146\/annurev-biochem-061516-044916","volume":"86","author":"T Mevissen","year":"2017","unstructured":"Mevissen T, Komander D. Mechanisms of Deubiquitinase Specificity and Regulation. Annu Rev Biochem. 2017;86:159\u201392.","journal-title":"Annu Rev Biochem"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02158-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-025-02158-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02158-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T05:01:19Z","timestamp":1743310879000},"score":1,"resource":{"primary":{"URL":"https:\/\/biosignaling.biomedcentral.com\/articles\/10.1186\/s12964-025-02158-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2158"],"URL":"https:\/\/doi.org\/10.1186\/s12964-025-02158-3","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]},"assertion":[{"value":"29 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal experiments are approved by the institutional review committee of Nanjing Medical University (No. IACUC-2201011). This study was conducted following the Declaration of Helsinki and was approved by the Institutional Review Board of the First Affiliated Hospital of Nanjing Medical University Ethics Committee (No. 2021-SR-135). Informed consents were obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"152"}}